

mMed™ Patent Portfolio

for mobile medication management

Contact: Napoleon Monroe at 718-427-3038
or nap.monroe@newdirectionsconsulting.net

Licensing through New Directions Technology Consulting, LLC

mMed Application: Monitoring of Advanced Injection Devices

New Directions Technology Consulting (New Directions) is the exclusive market developer of the mMed patent portfolio for mobile medication management.

With deep experience in injection devices, New Directions provides:

- Expertise in design, prototyping, clinical trials, manufacturing, marketing, regulatory compliance
- Software and services from cooperating companies
- Other intellectual property
- Relationships with universities that have:
- Staff who have published on medication management
- Facilities for supporting engineering and systems integration
- Patient populations for study
- Telemedicine monitoring capabilities
- Other infrastructure

Cost of failure to manage medication is well recognized

Importance of Advanced Injection Devices:

- Enable treatment outside institutional settings, which can reduce direct medical costs and cost of lost productivity (PT, caregivers, employers)
- Rising incidence of Diabetes and other chronic diseases
- Increased longevity lengthening cycles of treatment
- Emergency treatments require rapid onset provided by injection
- Biotech products cannot withstand first pass metabolism
- New injectable meds, including groundbreaking emergency treatments, are pending approval. Some are controlled drugs.
- Future personalized products often proteins or peptides
- Many companies expanding in advanced injection systems
- Pumps are not for everyone and the artificial pancreas is still far away
- Injections present special challenges
- Co-morbidities lead to added complexity of medication management challenges

Benefits of Adding Web-based Medication Management to Advanced Injection Devices:

- Better patient control
- Encourages medication adherence, compliance, management
- Improved outcomes
- Improved quality of life
- Lower overall costs
- Helps meet REMS requirements and limit liabilities
- Improves concordance among all stakeholders
- Apps available to integrate biological markers (blood glucose, A1c) lifestyle, other vitals to determine when injection is required
- FDA systems and standards for mobile technologies becoming better developed

Improves concordance between manufacturers, practitioners, caregivers and patients



www.newdirectionsconsulting.net and www.mMedhealth.com

*mMed is a trademark of New Directions Technology Consulting, LLC.
Henry Schein, Inc., is the assignee of the patent portfolio.*